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ABSTRACT: TRPM8 ion channels, the primary cold sensors
in humans, are activated by innocuous cooling (<28 °C) and
cooling compounds (menthol, icilin) and are implicated in
sensing unpleasant cold stimuli as well as in mammalian
thermoregulation. Overexpression of these thermoregulators in
prostate cancer and in other life-threatening tumors, along
with their contribution to an increasing number of pathological
conditions, opens a plethora of medicinal chemistry oppor-
tunities to develop receptor modulators. This Perspective
seeks to describe current known modulators for this ion
channel because both agonists and antagonists may be useful
for the treatment of most TRPM8-mediated pathologies. We
primarily focus on SAR data for the diﬀerent families of
compounds and the pharmacological properties of the most promising ligands. Furthermore, we also address the knowledge
about the channel structure, although still in its infancy, and the role of the TRPM8 protein signalplex to channel function and
dysfunction. We ﬁnally outline the potential future prospects of the challenging TRPM8 drug discovery ﬁeld.
1. INTRODUCTION
The family of TRP channels comprises 28 members, clustered
in eight subfamilies (TRPA, TRPC, TRPM, TRPML, TRPN,
TRPP, TRPV, and TRPY) that function as molecular cellular
signal integrators.1−4 Among them, the so-called thermoTRPs
are activated by diﬀerent temperatures, ranging from painful
levels of heat (TRPV1 and TRPV2) to nonpainful warmth
(TRPV3 and TRPV4), innocuous cool (TRPM8), and noxious
cold (TRPA1). Despite their role as sensors for temperature,
these channels also act in response to voltage, mechanical
stimuli, and endogenous and exogenous molecules.5−9 It has
been shown that diﬀerent syndromes result from mutations or
changes in the activities of TRP channels, including sensory
deﬁcits, abnormal sensitivity to pain, certain cancers, asthma,
and even cardiovascular, gastrointestinal, and neurodegener-
ative diseases. This fact makes TRP channels exciting targets for
drug development, although the eﬀorts made in this ﬁeld,
especially in the search for TRPV1 antagonists, have not yet
been fully successful, and the ﬁrst compound in clinical use is
still to come.9,10
Along with TRPV1 and TRPA1, transient receptor potential
melastatin 8 (TRPM8, also known as Trp-p8 or MCR1) is one
of the most studied thermoTRP channels in relation to its
physiological and pathological implications, and the search for
new modulators occupies the eﬀorts of diﬀerent pharmaceutical
companies and academic groups. Initially identiﬁed from the
prostate,11 TRPM8 channels are widely distributed in diﬀerent
tissues (subsets of sensory neurons innervating skin and
mucosae,12−14 the male urogenital tract,15 lung epithelium
cells,16 and artery myocytes17), although their speciﬁc role in
many cases still remains to be completely elucidated. This is a
Ca2+-permeable, nonselective cation channel that exhibits
polymodal gating mechanisms, being activated by innocuous
cool to cold temperatures (10−28 °C),18,19 membrane
depolarization,20,21 cooling agents like menthol and icilin,20,22
and diﬀerent synthetic molecules.12,23−25 The enhanced
sensitivity to innocuous cold (allodynia) and to mildly noxious
stimuli (hyperalgesia), occurring after nerve injury or
inﬂammation, have been correlated with an augmented
expression of TRPM8 in sensory neurons.26,27 Other
experimental evidence indicates that activation of TRPM8
channels resulted in attenuating pain in inﬂammatory and acute
pain states,28 as described in more detail in the following
section. In recent years, as discussed in section 3, the up-
regulation of TRPM8 expression has also been correlated with
the evolution of androgen-sensitive prostate cells and other
malignancies.11,29
As for other ion channels, a point of debate arises from the
possibility that both agonists and antagonists can be used for
the same therapeutic indication. This comes from the fact that
these channels do not have two discrete states only, open
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(conducting) and closed (nonconducting), but also an
inactivated/desensitized state, which after long exposure to
agonists or continuous stimulation are not able to conduct ions
across because the channel gate closes (Figure 1).30 For TRP
channels, calcium entry into the cell seems to be the primary
event leading to desensitization.30 It has been demonstrated
that TRPM8 channels are activated by PI(4,5)P2 through
putative interactions with the TRP domain and that cold or
menthol increases the apparent aﬃnity of TRPM8 channels for
this endogenous ligand.31 More importantly, desensitization of
the TRPM8 receptor, and probably of other TRP channels, is
mediated by PI(4,5)P2 depletion, triggered by a Ca
2+-sensitive
phospholipase C (most likely PLCδ1) stimulated after cell Ca2+
inﬂux and that resulted in PI(4,5)P2 hydrolysis.
31,32
The implications of TRPM8 channels in the above indicated
physiopathological conditions underscore their potential as
valuable pharmacological targets for therapeutic intervention,
not only for the diagnosis/prognosis of prostate cancer and
other tumors but also in the search for innovative analgesics
and antitumor agents.10,33 Although comprehensive reviews on
the pharmacology and therapeutic potential of TRPM8
modulators have already appeared,12,23−25,33 here we oﬀer a
general overview of the ﬁeld, with focus on medicinal chemistry
aspects extracted from primary research articles and patents.
Sections 5 and 6 describe the most important agonist and
antagonist chemotypes, with indication of structure−activity
relationships, whenever possible, and the in vitro and in vivo
pharmacological characterization of the most prominent
derivatives. The progression of a few compounds into clinical
development will be also commented upon. Some recent
contributions related to the indirect assessment of the TRPM8
structure (section 7) and the advanced knowledge of the
modulation of these channels by diﬀerent endogenous
molecules (section 8) are also included. This information
could provide important clues for upcoming drug discovery
programs based in this challenging but high potential
therapeutic target.
2. TRPM8, INFLAMMATION AND PAIN
Pain is deﬁned by the International Association for the Study of
Pain (IASP) as an “unpleasant sensory and emotional
experience associated with actual or potential tissues damage
or described in terms of such damage”.34 Pain results from
activation of specialized peripheral nerve ﬁbers, called
nociceptors, by a noxious stimulus.35 The cell bodies of
nociceptors are located in the dorsal root ganglia (DRG) for
the body and the trigeminal ganglion (TG) for the face and
have both a peripheral and central axonal branch that innervates
their target organ and the spinal cord, respectively. These
receptors respond to various external stimuli: mechanical (i.e.,
pressure, tumor growth, incision) thermal (i.e., hot or cold), or
chemical (i.e., ischemia or infection). Pain represents a key
evolved survival mechanism to detect potentially damaging
stimuli and thereby warn of the risk of injury. Unlike acute pain,
pain arising after a lesion or disease of the peripheral or central
nervous system (inﬂammatory and neuropathic pain) is often
persistent, a chronic state. Hypersensitivity to mechanical,
thermal, and/or chemical stimulation is one of the hallmarks of
inﬂammatory and neuropathic pain, which can manifest in the
form of allodynia and/or hyperalgesia.36−38 Hypersensitivity
has been associated with increased excitability of nociceptor
neurons as a result of changes in the expression of ion channels,
receptors, and mediator substances involved in the transduction
processes.36,39 TRP channels are involved in these processes
and play an important role in the ﬁrst step of primary aﬀerent
sensitization.40 Therefore, their modulation has been consid-
ered, in the past decade, a prominent approach to develop new
therapies for chronic pain syndromes.41,42 Identifying the
mechanisms used by nociceptors to transduce noxious cold has
lagged behind progress in understanding heat transduction
mechanisms.43,44
TRPM8 channels are expressed by ≈5% of all somatosensory
neurons, including mostly small-diameter, unmyelinated C-
ﬁbers as well as a minor group of lightly myelinated Aδ ﬁbers in
dorsal root ganglia (DRG) and trigeminal ganglia (TG) and
have been identiﬁed as candidates for cold sensing.45−48 A
subset of the TRPM8-positive cells may coexpress TRPV1 and/
or CGRP but are not labeled by other known somatosensory or
nociceptive markers (e.g., purinergic receptors, IB4 lectin, or
neurotrophin receptors), placing them in their own anatomi-
cally and functionally unique subpopulation of primary aﬀerent
neurons.49,50 In vivo, TRPM8 knockout mice are deﬁcient in
detecting innocuous cool temperatures and exhibit a partially
defective phenotype in responding to both normal (acute) cold
sensation and injury-evoked cold hypersensitivity. However,
low temperature (>5 °C) induced cold pain was intact in these
animals.51−54
Figure 1. Simpliﬁed scheme of TRPM8 channels at diﬀerent states (resting, open, desensitized, and blocked).
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Activation of TRPM8 by the agonist menthol or icilin
decrease nociceptive response in several animal pain models,
including neuropathic pain caused by chronic constriction
injury (CCI), inﬂammatory pain induced by injection of
complete Freund’s adjuvant (CFA), and a peripheral
demyelination model of inﬂammatory and neuropathic
pain.27,55 Also, TRPM8 activation with icilin leads to potent
anti-inﬂammatory eﬀects with decreased mucosal damage in
two diﬀerent models of chemically induced colitis (DSS,
TNBS) that are not observed in TRPM8-null mice.55
Paradoxically, TRPM8 antagonism may also provide relief
from some forms of pain. For example, TRPM8 knockout mice
failed to develop cold allodynia after chronic constriction injury
or CFA injection.56 Similarly, a TRPM8 antagonist reduced
cold allodynia in a chronic constriction injury model of chronic
neuropathic pain, thus recalling the phenotype of genetic
deletion.57 Lastly, it has been shown that the administration of
TRPM8 agonist menthol induced behavioral visceral pain-like
responses in a mouse colitis model, which decreased by
pretreatment with a speciﬁc TRPM8 channel blocker.58 Zou et
al., observed also an exacerbated cold hypersensitivity in an
orofacial neuropathic pain model rat after treatment with
menthol, a cold allodynia/hyperalgesia that was alleviated after
administration of a TRPM8 inhibitor.59
Recently, diﬀerent work showed that the ablation of TRPM8
aﬀerents in the adult mouse leads to more profound deﬁcits in
cold behavior compared to TRPM8 knockout animals.60 These
results suggest the presence of TRPM8-independent trans-
duction mechanisms in TRPM8 neurons, thereby providing
cold sensitivity in the absence of TRPM8 channels. Other
receptor molecules that have been linked to cold transduction
include TRPA1,61 channels involved in signal propagation, such
as Kv1 and two-pore (K2P) potassium channels,62,63 and the
sodium channels Nav1.8 and Nav1.9.64,65 In addition to acute
responses, cold pain associated with inﬂammation and nerve
injury was signiﬁcantly attenuated in ablated and knockout
mice. Moreover, cooling-induced analgesia after nerve injury
was abolished in both genotypes. These data conﬁrm previous
reports on the involvement of TRPM8 in cooling-induced pain
relief27 but show for the ﬁrst time the absence of analgesia in
TRPM8 knockout mice in a neuropathic pain model and
demonstrate that this pain-relief mechanism requires signaling
via TRPM8 aﬀerent nerve ﬁbers. Importantly, TRPM8-deﬁcient
mice retain normal sensitivity to noxious heat and mechanical
stimuli, demonstrating speciﬁcity of the observed phenotypes
for cold sensation as well as functional separation of these
somatosensory/nociceptive modalities. This observation was
conﬁrmed in a recent study with spinal nerve-ligated (SNL)
rats treated with a topical TRPM8 agonist, a 1,2,4-triazole
derivative 1 (M8-Ag).66 This agonist inhibited neuronal
responses to innocuous and noxious cooling in SNL rats,
with no eﬀect in the control group, and did not alter neuronal
responses to mechanical, heat, or brush stimulation.
Preclinically, TRPM8 has been functionally linked to pain in
oxaliplatin-induced67 and chronic nerve injury neuropathic pain
models,28,68 where increased receptor expression and sensitivity
to menthol or icilin were observed. In oxaliplatin-treated cancer
patients, an increased sensitivity to menthol suggests TRPM8
overexpression or potentiation of its activity.69 This preclinical
evidence for TRPM8 ion channels as a novel analgesic target
has been translated to clinical beneﬁt in patients with cancer-
associated neuropathic pain, one of the most feared symptoms
in cancer, particularly in terminally ill patients. Recently, Fallon
et al.70−72 reported the analgesic beneﬁt from the application of
topical menthol to treat chemotherapy-induced peripheral
neuropathy (CIPN) and post-mastectomy pain syndrome
(PMPS). The ﬁrst clinical results showed that the 82% of
evaluable patients had an improvement in their total pain scores
after 4−6 weeks of treatment. Fifty percent had a clinically
relevant reduction in pain scores of at least 30%, allowing
continuation of life-prolonging treatment.
Finally, patients with idiopathic detrusor overactivity have
increased TRPM8 expression in bladder sensory neurons.73
These patients also show involuntary sustained bladder
contractions and reduced bladder threshold volumes in
response to installation of ice-cold water into the bladder, an
eﬀect absent in healthy adults.74 In addition to a potential role
in cold detection and pain, TRPM8 has been demonstrated
preclinically to have a fundamental homeostatic role in the
control of core body temperature, with TRPM8 antagonists
causing signiﬁcant hypothermia.75 However, Winchester et al.76
have demonstrated that the use of selective TRPM8 antagonists
induce analgesia in an experimental model of cold pain in
humans, with eﬃcacy equivalent to the therapeutically relevant
semisynthetic opioid oxycodone and without a concomitant
change in core body temperature.
The involvement of TRPM8 channels in migraine is one
aspect of the pain ﬁeld that still remains unclear. Migraine is a
very common neurobiological headache disorder associated
with nausea, vomiting, and photo- and phonophobia symptoms
that is caused by increased excitability of the CNS. It ranks
among the world’s most disabling medical illnesses.77 Indirect
evidence, such as expression and function of TRP channels in
the cortex and trigeminal aﬀerent ﬁbers, suggests a mechanism
for the initiation of migraine pain by activation, among others,
of TRP channels on meningeal nociceptors after cortical
spreading depression (CSD) or local inﬂammation.78,79
Identiﬁcation of common genetic variants associated with
migraine susceptibility has been a real breakthrough in the
understanding of migraine molecular bases as well as in
determining a potential TRPM8−migraine relationship.80 The
identiﬁcation of a TRPM8 gene variant (2q37.1, rs10166942) is
associated with increased susceptibility to common migraine. In
2015, a re-evaluation of key ﬁndings from candidate gene−
migraine association studies provided clear evidence for the
involvement of TRPM8 in migraine and showed no evidence
for the participation of TRPV1 and TRPV3.81,82 The exact role
of the TRPM8 variant is unknown, as is the association of
TRPM8 and migraine. However, these data allow hypothesizing
that, regardless of being or not being a migraine speciﬁc
susceptibility gene, this TRPM8 variant may have a role in more
general pain sensitivity mechanisms such as the cutaneous
allodynia present in the majority of migraine patients.
3. TRPM8 IN CANCER
Cancer is a life threatening disease and, even though a plethora
of cancer drugs exist for various ailment types, current
treatment regimens have important associated problems, and
for many cancer types there is still no known cure. In this
respect, the number of TRP channels that have been linked to
carcinogenesis and tumor progression has considerably
increased in recent years.83−87 TRPM8 channels are overex-
pressed in a number of malignant tumors, especially solid
tumors, being involved in diﬀerent stages of cancer develop-
ment, proliferation, migration, and invasion.88,89
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In 2001, L. Tsavaler and co-workers reported the
identiﬁcation of a new gene trp-p8, which was preferentially
expressed in normal prostate epithelial tissue and up-regulated
in prostate tumor cells.11 The polypeptide (1104-mer) encoded
by this gene showed a very high homology to a human-
melastatin TRP channel identiﬁed a year later by G. Reid and
M. L. Fonta,90 who described a new ionic channel activated by
cool and sensitized by menthol, the TRPM8 channel.11
Tsavaler et al. observed that the overexpression of TRPM8 in
prostate cells correlates with rate of prostate cancer
progression. Their studies also revealed the overexpression of
trp-p8 gene in a number of neoplastic tissues other than
prostatic, like breast, colon, lung, and skin.
The expression of TRPM8 in prostate cells is closely related
to androgen receptor (AR) activity, being clearly down-
regulated in cells in which this activity is cut out.91−93 In fact,
Prevarskaya and co-workers demonstrated that TRPM8
expression is AR controlled in normal, hyperplasic, and
cancerous human prostate apical cells, while the loss of
TRPM8 expression can be connected to either a high grade of
tumor development, with undiﬀerentiated cells (metastasis), or
to a AR-independent tumor, where androgen receptor is not
expressed.93 Moreover, TRPM8 expression has been observed
in the androgen-dependent prostate cancer (PCa) cell line
LNCaP but not in the androgen-independent PCa cell lines
PC-3 and DU-145.11,91 However, expression of TRPM8 in the
androgen-independent PC-3 cells was reported later by Zhang
et al.92 Several experiments modulating TRPM8 expression in
the androgen-sensitive cell line LNCaP by using menthol and
cooling as activators of the channel, and capsazepine as channel
antagonist, provided evidence of the role of TRPM8 as
mediator of Ca2+ inﬂux and release from intracellular stores, in
both plasma membranes and in the endoplasmic reticulum.92,94
These results together with those of siRNA experiments
conﬁrmed that normal function of TRPM8 is required for
tumor cell survival. Later research showed that TRPM8 is
expressed both in the plasma membrane, TRPM8PM, and in the
endoplasmic reticulum, TRPM8ER. TRPM8PM channel is found
only in highly diﬀerentiated prostate epithelial cells, while
TRPM8ER is not dependent on the diﬀerentiation status.
Further experiments revealed that functional AR seems to be
mandatory for TRPM8PM activity, while TRPM8ER activity is
independent. They also observed that the transition to PCa
upregulated TRPM8 expression is both in plasma membrane
and reticulum. It was suggested that TRPM8PM is important for
the Ca2+ signaling involved in proliferation, while TRPM8ER
can be considered essential in controlling the growth of
advanced PCa metastatic cells.95 This hypothesis is consistent
with the model proposed by Hendriksen et al., in which
progression from high-grade PCa to metastasis is mediated by
selective downregulation of the AR pathway genes.96 It seems
clear then, the beneﬁt of androgen-ablation therapy in early
stages of prostate cancer, but still there are doubts about the
role of TRPM8 in the androgen-independent cell lines and in
advanced grade tumors. Recent work of Zhu et al. proved that
artiﬁcial overexpression of TRPM8 in the AR-independent
cancer PC-3 cell line, in vivo, has a negative eﬀect on the
proliferation and angiogenesis progression. These results open
new opportunities for the potentiation of TRPM8 channels as
treatment for patients in advanced stages of cancer and
metastasis.97
Despite all these results that link TRPM8 to prostate
carcinogenesis and tumor progression, there was still
controversy around whether the aberrant expression of
TRPM8 in PCa is the origin or the result of tumor
development. Pardo and co-workers designed several experi-
ments that shed light on this question. They studied the
consequences of TRPM8 silencing, both pharmacologically
blocking and siRNA experiments, and showed that proliferation
was reduced in all tumor prostate cells tested, but not in normal
prostate cells. It seems that the proliferation of normal cells is
not aﬀected by TRPM8 downregulation. These interesting
results support the idea that TRPM8 plays a tumor speciﬁc role
in tumor proliferation instead of being a mere consequence of
tumor development.98
Concerning diagnoses, the biomarker currently used in clinic
for prostate cancer, is the prostate-speciﬁc antigen (PSA).
However, its usefulness is questionable because PSA can be
found in serum samples of both PCa patients and patients with
benign prostatic hyperplasia. Moreover, the PSA levels are quite
similar in patients with localized/quiescent PCa and in patients
with metastasis.99 The higher presence of TRPM8 compared to
PSA in malignant tissue samples in comparison to non-
malignant ones suggests TRPM8 as a useful biomarker for PCa
diagnosis.100 Bai et al. found that TRPM8 levels in urine and
blood of patients with metastasis were signiﬁcantly higher than
in patients with localized cancer that have undergone radical
prostatectomy as well as than those of healthy men. These
ﬁndings suggest that TRPM8 levels in body ﬂuids can be a
useful prognosis biomarker, which will allow clinically localized
and metastatic prostate cancer to be distinguished. Their
experiments also conﬁrmed the role of TRPM8 in androgen
regulated proliferation of prostate cancer cells, although they
are in some ways contradictory with the results found for
TRPM8 expression in organ tissues.101
The number of tumors in which upregulation of TRPM8 has
been detected has increased in the past decade. Tsavaler et al.
already reported it in lung, skin, breast, and colon cancer
tissues.11 Since then, it has also been identiﬁed in neuro-
blastoma, osteosarcoma, urothelial carcinoma, in which it was
associated with poor survival, and pancreatic adenocarcinoma,
where it was shown to correlate with tumor stages.89 Chodon et
al. found correlation between TRPM8 expression and the
breast cancer grade in the MCF-7 cell line, and interestingly
they also found correlation with estrogen receptor alpha (ERα)
levels.102 This proves that the regulation of TRPM8 in breast
cancer cells is hormonally dependent, which is in agreement
with the androgen-dependent regulation of TRPM8 in prostate
cancer cells.11,93 Additionally, experiments performed by
Okamoto et al. suggest that TRPM8 channels are functional
on the plasma membranes in human oral squamous carcinoma
cell lines HSC3 and HSC4.103 Experiments to assess the
biological response to TRPM8 agonists and antagonists
demonstrated that the stimulation of TRPM8 increases
MMP-9 activity, while its blockade has the opposite eﬀect,
which is consistent with the increased metastatic potential
induced by TRPM8.103 The group of Yee has demonstrated
that TRPM8 is consistently overexpressed in human pancreatic
adenocarcinoma cell lines and tissues and that patients with this
type of tumor aberrantly exhibit immunoreactivity against the
TRPM8 channel.104,105 They also showed that RNAi-mediated
silencing of the TRPM8 gene stimulates replicative senescence,
thus suggesting that abnormally expressed TRPM8 channels
could contribute to pancreatic tumorigenesis.105
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4. TRPM8 IN OTHER PATHOLOGICAL CONDITIONS
Apart from inﬂammation and cancer, TRPM8 channels are
related to other pathological conditions, although they have
been less studied and their role is less established.85
For instance, there is evidence that links TRPM8 channels to
respiratory disorders. Thus, the mitigating eﬀects of menthol in
the irritant responses to certain tobacco smoke constituents had
been reported.106,107 These eﬀects were reversed by treatment
with a TRPM8 antagonist. Stimulation of TRPM8 channels can
be harmful in patients with asthma and also with chronic
obstructive pulmonary disease (COPD). In fact, cold-induced
airway hyperresponsiveness can either induce asthma or
exacerbate COPD and asthma, increasing morbidity. Cold-air
inhalation causes airway constriction and can induce asthma
associated with, for instance, winter sports.107,108 These
observations suggest the implication of TRPM8 channels
both in physiological and pathological respiratory processes.
TRPM8 channels are also implicated, together with other
TRPs (mainly TRPV1), in bladder sensation, showing high
potential as therapeutic targets for lower urinary tract
dysfunction (LUTd).109 Several studies suggest the relevant
role of TRPM8 in disorders like bladder pain syndrome and
bladder hyperactivity.109,110 The observation of upregulation of
TRPM8 in bladder tissues of patients with painful bladder
syndrome or idiopathic detrusor overactivity (IDO), in
comparison to healthy controls, points in this direction, but
the correlation of TRPM8 expression and these abnormalities
still remain unclear.111
Concerning obesity, there are two types of adipose tissue in
mammals, white (WAT) and brown (BAT). BAT is in charge
of energy expenditure through the activation of the UCP1
protein, inducing thermogenesis, which can prevent develop-
ment of obesity. Work reported by Ma et al. showed that
menthol promotes the overexpression of UCP1 in cultured
brown adipocytes from wild-type mice but not in TRPM8-
deﬁcient mice.112 Recent work reported by Rossato et al.113
showed that menthol or icilin activation of TRPM8 in WAT
enhanced UCP1 expression, having as a consequence an
increase in glucose uptake and heat production. The authors
interpret these results as induction of the brown phenotype in
white adipocytes, which points to TRPM8 as a potential target
for the treatment of obesity.113 Moreover, certain connections
between TRPM8 gene polymorphisms and obesity-related
metabolic syndrome have also been established.114
TRPM8 has also been detected in blood vessels, being the
most abundant among the TRP channels in these tissues.115,116
TRPM8 expression has been observed in several rat arteries,
and its activation by menthol or icilin promoted vasodilation.
This vasodilation, induced by systemic administration of
menthol, may be responsible for the fall in arterial blood
pressure observed in an in vivo study in rabbits and cats. It has
also been reported that the vasoconstriction or vasodilation
depends on the previous vasomotor tone and that it is mainly
mediated by TRPM8 activation on smooth muscle cells.17
Although results of other research in this area are in agreement
with these observations,117−119 further research is still required
to conﬁrm the role of TRPM8 in vasodilation-related processes.
Experimental studies from the group of Belmonte and co-
workers showed that reduction of temperature and subtle
osmolality increases can stimulate DRG and TG neurons
expressing cold-sensitive TRPM8 channels, which act as
regulators of surface wetness of exposed body mucosae, like
the eye.120,121 Therefore, another function of the TRPM8-
expressing neurons is to act as regulators of ocular wetness
through the modulation of the blink rate, thus predicting new
opportunities for the understanding and treatment of dry eye, a
common ophthalmological disorder that increased with age.
5. TRPM8 AGONIST CHEMOTYPES
5.1. Menthol and Derivatives. Chemical modiﬁcation of
endogenous ligands or natural products, capable of interfering
with a given receptor, is a widely used strategy in medicinal
chemistry programs.122,123 Therefore, not surprisingly, the
exploration of menthol-derived compounds emerged shortly
after the discovery that menthol activates TRPM8 channels,45
with ester derivatives like Frescolat ML,124 carboxamide
analogues such as 2 (WS-12, Figure 2),125 described as the
ﬁrst high-aﬃnity TRPM8 ligand,125 and ﬂuorinated analogues
claimed as the basis for diagnostic agents.126,127 Sherkheli et al.
also quantiﬁed the activation of TRPM8 channel by several
Figure 2. Menthol and derived TRPM8 agonists.
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menthol carboxamide derivatives, some of which were initially
prepared by Wei, E.T. et al., ﬁnding up to 10-fold lower EC50
values than of the parent menthol.128 It seems that the
cyclohexyl ring, characteristic of menthol, is behind the
enhanced selectivity of the most representative derivatives in
this series, 2, 3 (WS-5),128 and 4 (CPS-125)128 (Figure 2)
when compared to lower homologues and linear analogues.
Dendreon Corporation described related derivatives in
several patents. Their menthol-derived small-molecules, illus-
trated by compounds 5−7, are able to activate TRPM8 with
nanomolar potency.129,130 In this family of compounds, the
substituted cyclohexyl moiety and the free amino groups appear
to be structural requirements for good agonist activity, while
the carboxamide substituent can be replaced by bezimidazolone
(D3263, 5), phenyl (6), and substituted ethyl (7) derivatives.
In addition to increasing Ca2+ entry in CHO cells expressing
TRPM8, selected compounds from this series prove to
stimulate cancer cell apoptosis and substantially reduce
xenograft tumors in animal models of human prostate cancer
without showing apparent toxicity. Compound 5, which
showed good oral bioavailability, entered phase I clinical trials
in 2009 for the assessment of safety, determination of the
maximum tolerated dose, and characterization of the
pharmacokinetic proﬁle after a single dose and repeated daily
dosing (NCT00839631). In men with advanced prostate
cancer, preliminary results indicated that this compound is
able to stabilize the disease. Apart from elevations in Troponin-
T, no signs of cardiac toxicity were observed (maximum
tolerated dose: 100 mg/day).131 The last update of data at
ClinicalTrials.gov was on April 30th, 2012. Some preclinical
data also demonstrated the potential of 5 to treat benign
prostatic hyperplasia by itself or in combination with the
synthetic 5α-reductase inhibitor ﬁnasteride (additive eﬀect).
Some diastereomeric menthol ethers, like 8, have been
described in a recent Japanese patent to display nanomolar
activation of TRPM8 receptors.132 Menthol-related cyclo-
hexane−hydantoin spirocyclic derivatives, as well as pyrazolyl-
5-one and pyrimidinetrione analogues, have also been claimed
as TRPM8 eﬀectors (structures not disclosed).133
In addition to numerous studies on its applications in
cosmetics, which are not described here, there are several
clinical trials evaluating the usefulness of menthol alone or in
combination with other active principles as a therapeutic agent.
A few of these studies are recorded here, including their
ClinicalTrials.gov identiﬁer number. Thus, menthol alone or
Biofreeze, a topical lotion containing menthol and alcamphor, is
being examined for treating pain symptoms in slaughterhouse
workers with symptoms of carpal tunnel syndrome
(NCT01716767), as a topical counter-irritant on cutaneous
pain and hyperalgesia provoked by topical application of
TRPA1-agonists (NCT02653703), to alleviate shoulder pain
(NCT01827306), musculoskeletal disorders associated with
neck pain (NCT01542827), and persistent neuropathic pain
from chemotherapy among breast and colorectal cancer
patients (NCT01855607).
An invention by researchers at the Edinburgh University also
claims that activation of TRPM8 channels induces analgesia in
chronic neuropatic pain states.134 Therefore, activation agents
including menthol and menthyl derivatives, among others,
could be useful for the treatment of diseases and conditions
which involve neuropathic pain, such as that induced by
trauma, demyelination, cancer or inﬂammatory states, phan-
tom-limb, back and bone pain, and chemotherapy neuropathy.
As a potential alternative for the prevention and treatment of
hypertension, the Third Military Medical University is
evaluating the eﬀects of menthol on blood pressure in
hypertensive patients (a double-blind phase II clinical study,
NCT01408446).
Studies performed with two diﬀerent human melanoma cell
lines expressing TRPM8 reported the dose-dependent in vitro
cytotoxic eﬀects of menthol.29,135 Chanchao and co-workers
had in fact stated an eﬀectiveness comparable with that of 5-
FU, with the advantage that menthol has no toxicity while the
side eﬀects of 5-FU are multiple and non-negligible.135 Menthol
also showed a signiﬁcant decrease of viability of a bladder cell
line T24, inducing cell death through TRPM8 activation.136
Inventors from the Miguel Hernańdez University have
patented that the TRPM8 receptor is linked to the control of
lacrimation and that its activation with agonists, like menthol,
increased tearing, thus leading to a promising remedial for the
dry eye condition.137 As agonists they studied menthol,
frescolat, geraniol, eucaliptol, icilin, and other cooling agents.
The invention also relates the use of TRPM8 antagonists as
useful treatment for epiphora (excessive tear production).
The activity and interest of various natural and synthetic
menthol derivatives, along with other cooling compounds that
behave as activators of thermoTRPM8, have been compiled in a
2012 comprehensive review.138
5.2. Pyrimidine Derivatives. Icilin is a synthetic
compound that behaves as an agonist of TRPM8 (about 200-
fold more potent than menthol)26,139 but also suppresses
TRPM8 current activation by other agonists22 and modulates
TRPV3140 and TRPA1.22 Therefore, icilin has been and
continues being used as a pharmacological tool for studying
TRP channels.141−143 Icilin has anti-inﬂammatory activity,55 has
been claimed for the treatment of diﬀerent neurological
disorders, as menthol and linalool,144 and reduces the activity
and expression levels of E2F1,145 a transcription factor
controlling the cell cycle in prostate cancer cells. The group
of De Petrocellis explored the preparation of new analogues by
modiﬁcation of the pyrimidin-2-one central scaﬀold of icilin in
an attempt to improve the therapeutic potential.146 Work at the
three rings of the icilin molecule demonstrated very narrow
limits for modiﬁcation. SAR studies point to the importance of
the presence and position of the o-OH and m-NO2 substituents
on the distal phenyl groups. The phenyl ring at the 1-position
of the pyrimidine central scaﬀold tolerates some variations, like
the addition of a methyl group in relative para position to the
OH or the presence of m-halogens (I < Br > Cl) in non-OH
analogues but always provided less potent compounds (Figure
3). Both a lower homologue of the central ring and
conformationally restricted tricyclic derivatives were totally
inactive.146
Structurally unrelated pyrimidine derivatives, exempliﬁed by
compound 9, produce cooling eﬀects on skin and mucous
Figure 3. Pyrimidine-derived TRPM8 agonists.
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membranes through the interaction with the TRPM8 receptor
(submicromolar potencies).147
5.3. Five-Membered Heterocycle Derivatives. In a
recent paper by R. Patel and co-workers, compound 1, with a
1,2,4-triazole central scaﬀold, was described to display more
potent antihyperalgesic eﬀects than menthol in a rat model of
neuropathic pain.66 This compound activates TRPM8 channels
with a 45 nM EC50 value and also TRPA1 thermoreceptors
although with lower potency (4 μM). It attenuates neuronal
responses after innocuous and noxious cooling and reverses
hypersensitivity to acetone-induced cooling in spinal nerve-
ligated (SNL) rats. Results from this study led the authors to
suggest that TRPM8 agonists might be beneﬁcial in neuropathy
without aﬀecting normal cold sensation.
The group of Ostacolo described the preparation of a family
of isoxazole derivatives and their preliminary characterization as
TRPM8 agonists.148 Some of the isoxazoles were more potent
than menthol (up to 200-fold), but most of them display lower
eﬃcacy (Figure 4). A few compounds, like 10, elicit stronger
antiallodynic responses than menthol in rats with chronic
constriction injury of the sciatic nerve.
5.4. Other TRPM8 Agonists. Diﬀerent plant-derived
natural products have been identiﬁed as TRPM8 agonists,
including eugenol,12 eucalyptol,124 geraniol,124 and neferine,149
all of them displaying moderate to low potency ranging from
μM to mM EC50 values (Figure 5). The activation/sensitization
to cold of mammalian TRPM8 seems to be responsible for the
enhancement of innocuous cold and noxious cold sensations
induced by camphor, which also potentiate heat sensations
through activation of TRPV1 and TRPV3 channels.150
5-Methyl-2-(1-pyrrolidinyl)-2-cyclopenten-1-one (11), iso-
lated from roasted malt,151 and some hybrid derivatives152
were identiﬁed as intense cooling compounds. Although
authors mentioned TRPM8 channels as cold-sensitive
receptors, no data is provided regarding the direct action of
these compounds on the mentioned thermoreceptor.
In patch-clamp experiments, eucalyptol, from eucalyptus oil,
evokes inward currents in TRPM8-expressing cells and also
behaves as a TRPA1 antagonist, while its regioisomer 1,4-
cineole activates both receptor types.153 Studying diﬀerent
small-molecules BASF SE identiﬁed new chemotypes able to
activate TRPM8 channels.147,154 Thus, a series of
tetrahydrofuro[3′,4′:5,6]pyrido[2,1-a]isoquinoline-dione deriv-
atives, exempliﬁed by compound 12, and diﬀerent secondary
caﬀeic-derived amides, like derivative 13, show submicromolar
potencies (Figure 5).
Wei described in a recent patent a series of new di-isopropyl-
phosphinoyl alkene (DIPA) compounds for the topical
treatment of sensory discomfort (itch, dermatitis, psoriasis,
and ocular discomfort, among others).155 In this series, the iPr
group is preferred over sec- or iso-butyl homologues and
optimal length for the linear aliphatic alkene is 6−9 carbon
atoms. These compounds elicit submicromolar EC50 values and
>5-fold increased potency compared to menthol (i.e., 14,
Figure 5). A related phosphine oxide, containing sec-butyl
substituents instead of iPr, was previously studied, showing a
dose-dependent and reversible activation of TRPM8 with an
EC50 value of 4.1 μM.
156
While studying a series of N-aryl and N-benzyl triptamine
derivatives to explore the structural requirements determining
TRPM8 modulation, Bertamino and co-workers described a
new compound able to activate the channels under
investigation (15, Figure 5).157 Thus, tryptamine derivative
15 displays signiﬁcantly higher potency (EC50 = 40 μM) than
menthol and a similar eﬃcacy under patch-clamp experiments.
6. TRPM8 ANTAGONIST CHEMOTYPES
During the past decade, several pharmaceutical companies and
a few academic groups have made enormous eﬀorts in the
search for new antagonists of the TRPM8 channel. The
diﬀerent families of compounds described to date are recorded
in this section, with an intended rational classiﬁcation, based
ﬁrst on the central structural scaﬀold and then, if necessary,
subcategorizing them by other secondary motifs.
6.1. N-Heteroaryl-N-benzyl Sulfonamides. 6.1.1. Benzo-
thiophene Derivatives. Several patents from Janssen claimed a
Figure 4. 1,2,4-Triazolyl- and isoxazolyl-derived TRPM8 agonists.
Figure 5. Natural products and other TRPM8 agonists.
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big family of benzothiophene-bearing N-benzyl sulfonamides
(examples 16−20) and related N,N′-disubstituted analogues
(21) as potent TRPM8 antagonists (Figure 6). A ﬁrst patent
describes 850 benzo[b]thiophene derivatives and some aza-
analogues through the combination of diﬀerent substituents at
position 3 of the bicyclic skeleton at the N-benzyl substituent
and at the sulfonyl moiety.158 Preliminary HTS evaluation was
performed in an in vitro canine TRPM8 functional assay,
measuring the changes produced by compounds in the
intracellular Ca2+ concentration induced by the agonist
(menthol or icilin). From the results of this assay, it can be
said that chlorine, bromine, or small alkyl groups are preferred
at position 3, while at the benzyl moiety a m- or p-ﬂuorine or
triﬂuoromethyl group, or a combination of them, favored
TRPM8 antagonist properties. Either alkyl or aryl groups at the
sulfonyl moiety are well tolerated. The antagonist properties for
the most promising compounds were conﬁrmed through patch
clamp experiments. Thus, representative compound 16 exhibits
high potency either in the hTRPM8 HTS assay (IC50: 4 nM) or
in patch clamp experiments (IC50: 1.1 and 2.3 nM, after
menthol and cold activation, respectively). The potent TRPM8
antagonist properties were conﬁrmed in diﬀerent animal
models by reversing carrageenan-induced heat hypersensitivity
(64% at 30 mg/kg, po) and CFA-induced thermal and
mechanical hyperalgesia (91% at 10 mg/kg, po). This
compound was also able to reduce icilin-stimulated “wet-dog”
shakes (WDS) in rats with an ED50 of 2.5 mg/kg, cold-evoked
cardiovascular pressor responses (75% of inhibition), and
acetone-induced hypersensitivity, an in vivo model of neuro-
pathic pain (69% pain relief, 30 mg/kg, po). A 18F labeled
analogue of 16, its related derivative 17, and the 11C labeled
compound 18 were also protected as useful tools for the
labeling and imaging of TRPM8 channels.159 One year after the
initial patent in this series, Janssen published an extension that
covered potent aminoethylsulfonyl derivatives, like 19, and
some less active naphthalene analogues.160 Closely related
sulfamides, exempliﬁed by compound 20 in Figure 6, also
aﬀorded TRPM8 antagonists with nanomolar potencies in the
HTS assay, although their eﬃcacy in animal models was not
revealed.161
At the beginning of 2012, Janssen published the US patent
20120053347 describing a new series of benzothiophene
derivatives, resembling to some extent previous series in this
section but bearing a phosphonate moiety instead of the initial
sulfonamide.162 The 3-bromothiophene 21, with a 9 nM IC50
value in the HTS functional assay and good antagonist in vivo
activities, is one of the most active compounds in this series.
Thus, this compound reverses up to 80% the icilin-induced
behaviors in rats (30 mg/kg, po), and several compounds
within this family are also active in the CFA-induced model of
hyperalgesia (ED50 up to 5.2 mg/kg). As it could be expected,
the conﬁguration of the asymmetric center of 21 is important
for the antagonistic activity, with its R-enantiomer showing one
order of magnitude lower potency. An initial SAR study,
Figure 6. TRPM8 antagonists: Compilation of representative N-benzothiophene sulfonamides and related compounds.
Figure 7. TRPM8 antagonists: representative N-benzimidazole sulfonamides and related compounds.
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including a part of the compounds covered by the patent, has
been published and highlights the preference for small alkyl
groups at position 3 of the benzothiophene ring and either
ethyl or isopropyl esters alongside the phosphonate.163
6.1.2. Benzimidazole Derivatives. A second family of
TRPM8 antagonists with a central N-sulfonamide motif
includes compounds substituted with a benzimidazole moiety
(examples 22, 23, Figure 7). Two patent applications protect
the TRPM8 antagonist activity of the mixtures of 1,3- and 1,2-
N-disubstituted derivatives, initially obtained after benzylation
of the corresponding 1-monosubstituted analogues.164,165 In
these series, lower alkyl groups at the N1 atom are well
tolerated (ethyl preferred), and one or two ﬂuorine atoms or a
CF3, or a combination of both, at the phenyl ring of the benzyl
moiety increase potencies with respect to unsubstituted
analogues, as it was also found for the incorporation of F or
CF3 at position 5 of the benzimidazole nucleus.
In general, the best compounds within these collections were
less potent than 2-alkene substituted benzimidazole related
derivatives, which displayed nanomolar potency in the canine
hTRPM8 Ca2+ ﬂux assay.166 A representative compound in this
new series, 24, is able to reverse cold hypersensitivity in a
model of neuropathic pain (oral 10 mg/kg, 91%) and icilin-
induced WDS (oral 30 mg/kg, 98%), even if it does not show
optimal PK properties regarding metabolism.167
Analogues of 24 bearing spiroheterocyclic systems in
position 2 of the central skeleton provided highly potent
TRPM8 antagonists, with IC50 values in the subnanomolar
range.168 In this series, the dihydroisoxazole ring is preferred
over the oxazole and imidazole at the spiro moiety. Compound
25 inhibits cold-stimulated currents in HEK cells expressing
hTRPM8, reverses icilin-induced behaviors in rats (98%, 10
mg/kg, po), and reduces neuropathic pain (acetone-mediated
hypersensitivity, 83%). This compound exhibits a good
pharmacokinetic proﬁle, with excellent oral bioavailability and
relatively high metabolic stability.57
Related azabenzimidazole derivatives, substituted with diﬀer-
ent ﬁve-membered ring heterocycles at position 2, here
represented by compound 26, are also claimed in a patent
application.169 Chlorine, alkyloxy, and substituted amines are
the groups of choice at the 7-position, while pyrazole ring
provided the most potent compounds among all the 2-
pentaheterocycles incorporated in this series.
6.1.3. Pyridine Derivatives. Two patents on N-benzyl-N-
pyridylsulfonamide structures, similar to those described in the
previous sections, have been disclosed by RaQualia Phar-
ma.170,171 In a ﬁrst series of 199 compounds, exempliﬁed by the
N-pyridine derivative 27 (RQ00203078, Figure 8),170 the
observed activities indicated the need for a 3-Cl atom on the
pyridine ring, combined with CF3, CH3, or Cl groups at
position 5. In addition, the incorporation of diﬀerent
substituents at the phenyl ring of the benzyl moiety either
maintain or improve the activity, as it does replacement of the
carboxylic acid by a hydroxymethyl group or diﬀerently
substituted carboxamides. In the second set of compounds,
the phenyl ring of the benzyl substituent has successfully been
replaced by diverse heterobicycles, like benzofuran, indole,
indazole, and benzotriazole derivatives. In these patents, the
inventors claimed good in vitro antagonist properties in
HEK293 and human malignant melanoma cell lines and also
indicated potent activities in diﬀerent in vivo models, although
there is no disclosed data. They also claim beneﬁcial eﬀects of
their compounds for neuropathic pain of cold- and static-
allodynia, icilin-caused WDS, oxaliplatin-induced pain, and
overactive bladder in rats suﬀering from cystitis. A recent paper
by this group reports that compound 27 attenuates the shaking
behavior with an ED50 of 0.65 mg/kg (po), indicating that this
sulfonamide derivative is a potent and orally active TRPM8
antagonist. This compound, which is commercially available as
a pharmacological tool, is also selective over other TRP
channels (A1, V1, V4) and has been selected as an advanced
compound for further investigation.172
Related analogues having a condensed pyridine moiety
(isoquinoline) have been patented by Mitsubishi Tanabe
Pharma Corporation (see compound 28 in Figure 8).173
Among these very potent compounds, the presence of the
cyclopropyl group is an important structural requirement, while
the tetrazole group (a carboxylic acid isostere) can be
substituted by other nitrogen-containing heterocycles, like
tetrazolone, 1,2,4-triazole, and 1,2,4-oxadiazole-5-one, and
even by CO2H, CO2Me, and CN groups without signiﬁcant
loss of antagonist activity. Similarly, diﬀerent groups are
allowed at the ortho position of the tetrazole moiety, with
Me, OMe, Cl, and NMe2 within the preferred ones.
In 2010, Glenmark patented a new family of compounds,
which keeps an N-heteroaryl (benzothiazole or benzoxazole)
and an N-benzyl moiety on a nitrogen atom but diﬀers from
previous series in the third N-substituent.174 Instead of the
sulfonyl appendage, these tertiary amines bear an alkylamino
moiety, as illustrated by compound 29. In this series,
unsubstituted benzo[d]thiazol-2-yl and benzo[d]oxazol-2-yl
led to potent derivatives and some aza analogues are acceptable.
The presence of F atoms (2- or 2,4-) or a 2-methyl group in the
benzyloxy moiety is coupled to high activity, as the m-OMe
group on the N-benzyl substituent.
6.2. Urea Derivatives. The (3-chloro-pyridin-2-yl)-piper-
azine derived urea (BCTC, 38) has been one of the ﬁrst
TRPM8 antagonists used for studying the pharmacology of this
channel (IC50: 0.8 μM, Figure 9).
124 This compound, which is
Figure 8. TRPM8 antagonists: representative pyridine-derived N-
heteroaryl sulfonamides and related compounds.
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commercially available, was initially prepared as a TRPV1
modulator (IC50: 35 nM) and therefore is a nonselective
TRPM8 antagonist. Probably, in the search for more potent
and selective TRPM8 antagonists, this compound inspired the
design and synthesis of other urea derivatives as those described
in the two following subsections.
6.2.1. Tetrahydroisoquinolines and Aza-analogues. In
2009, Amgen Inc. published two patents describing tetrahy-
droisoquinolines and aza-analogues as TRPM8 antagonists and
claimed their potential value for the treatment of diverse
pathologic conditions.175,176 In their eﬀorts to validate TRPM8
channel as a novel target for pain, they discovered a
tetrahydrothienopyridine derivative after a high-throughput
screening campaign. The initial hit was then modiﬁed to lead to
tetrahydroisoquinoline-urea analogues with higher potency and
increased metabolic stability.177 In this series, modiﬁcation at
the N-phenyl ring is restricted to the incorporation of F atoms
or its replacement by unsubstituted pyridine rings. Although
with suboptimal pharmacokinetic properties, compound 31
(Figure 9) reduces icilin-induced WDS in a dose-dependent
manner (80%, 30 mg/kg, po). Further optimization of potency
and pharmacokinetic properties aﬀorded analogues 32 and 33,
with hTRPM8 IC50 values of 10 and 12 nM, respectively, and
balanced properties that made them ideal for in vivo
evaluation.178 In the icilin induced rat “wet dog” shakes
(WDS) model, compound 32 achieves maximal inhibition at 10
mg/kg (po), while 33 results in 68% inhibition of WDS at 1
mg/kg and the icilin eﬀect was completely blocked at 3 mg/kg.
Compared to the initial hit 31, the higher in vivo activity of 33
was attributed to the increased drug plasma levels, which results
from the improved pharmacokinetic properties of the latter
molecule. This compound was selected for further progression
in preclinical models of pain.
6.2.2. Spiro[chromene-2,4′-piperidine] Derivatives. Follow-
ing an analogue-based rational design, synthesis, and screening,
Glenmark Pharmaceuticals discovered a set of spiro[chromene-
2,4′-piperidine]phenylureas that behave as TRPM8 antagonists
(see derivative 34 in Figure 9).179,180 Selected compound 34
shows nanomolar in vitro TRPM8 potency, moderate to high
metabolic stability in diﬀerent species, and quantiﬁable levels in
plasma up to 8 h postdose following oral administration. The R-
stereoisomer is more potent and more selective over other TRP
channels than its optical S-antipode. In in vivo models of
neuropathic pain, 34 is able to inhibit the acetone-induced
allodynia in rats (74%, 10 mg/kg, po), signiﬁcantly reduced the
icilin-induced WDS in mice (72% eﬃcacy, 30 mg/kg, po), and
produced a dose-dependent inhibition of paw licking after
oxaliplatin injury (100% eﬀect, 30 mg/kg, po).180
6.2.3. Other Urea Derivatives. Very potent TRPM8
antagonists, containing a central urea motif have been patented
by Bayer.181 Compound 35 is one of the most potent TRPM8
antagonist described to date, displaying subnanomolar potency
in the menthol-induced Ca2+ inﬂux in TRPM8-expressing
HEK293 cell assay (Figure 9).
6.3. Phenylglycine Derivatives. Another collection of
TRPM8 antagonists is that of N-arylphenylglycine amides,
described by Janssen Pharmaceutica (i.e., 36, Figure 10).182,183
This family comprises two libraries of 375 and 55 compounds
in which 2-arylpyrrolidine and isoquinoline substituents gave
better activities than other mono- and bis-heterocyclic systems.
Substituted phenyl and benzothiophene are preferred aryl
moieties at the α position of the amino acid. As expected, the
inﬂuence of the conﬁguration was crucial for the activity of
these Phg derivatives. Thus, compound 36 (S,S) shows 1 order
of magnitude higher potency than its (R,R) and (R,S) isomers,
while the (S,R) diastereoisomer undergoes more than 100-fold
drop in the antagonist activity, indicating a larger inﬂuence on
the activity of the pyrrolidine stereogenic center than that of
the Phg residue. Compound 36 demonstrated good in vivo
eﬃcacy, reducing WSD in rats produced after administration of
icilin.183
Related phenylglycine amides, combining either a diﬀerently
substituted N-(R)-inden-1-yl ring or a 1-phenylethyl group with
an N-acyl moiety, bearing aryl- or heteroaryl groups, have been
recorded in two recent patents by Kissei Pharmaceutical.184,185
Preferred compounds from these series are able to reduce the
Figure 9. TRPM8 antagonists: representative urea derivatives.
Figure 10. TRPM8 antagonists: illustrative phenylglycine derivatives.
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icilin-evoked wet dog shakes in rats (i.e., derivative 37, 100%
inhibition at 3 mg/kg). These compounds also elongate
signiﬁcantly the micturition interval in guinea pigs (up to
221% at 0.5 mg/kg/mL).
6.4. Tryptamine Derivatives. The structural requirements
behind TRPM8 modulation were also explored by means of a
series of N-substituted tryptamines. Apart from the already
mentioned agonist 15, most derivatives within this series
behave as TRPM8 antagonists, with the (N,N-dibenzyl-2-(1H-
indol-3-yl)ethanamine (38) as the most potent inhibitor of
calcium inﬂux in HEK293 cells.157 Perfusion of tryptamine
derivative 38 (3 μM) produced a complete inhibition of
menthol-induced TRPM8 currents measured at +80 mV, with
Figure 11. TRPM8 antagonists: selected tryptamine derivatives.
Figure 12. TRPM8 antagonists: archetypal tertiary amide derivatives.
Figure 13. Structure of other structurally diverse TRPM8 antagonists.
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kinetics slower than that observed for 30 (BCTC) but
increased potency (38, IC50 = 367 nM).
5-Substituted tryptamine derivatives were also identiﬁed as
antagonists of TRPM8 after screening of the Renovis corporate
collection and further evaluation of commercial analogues.186
Compound 39, identiﬁed as the most potent tryptamine
derivative within this family, lacks selectivity because it is a
known ligand of 5-HT receptors (Figure 11).187
Voacangine, a conformationally restricted tryptamine-derived
natural product, competitively displaces menthol, but not icilin,
from TRPM8 receptors (IC50 = 9 μM).
188 This compound is a
stimulus-selective antagonist because it did not abrogate cold-
induced channel opening but inhibited chemical agonist-
provoked TRPM8 activation. In addition, voacangine com-
petitively inhibits capsaicin binding on TRPV1 and blocks
capsaicin- and heat-induced activation of this thermoreceptor,
and shows some TRPA1 agonist activity.
6.5. Tertiary Amide Derivatives. A collection of 177 2-
benzyloxy-benzoic acid amide derivatives were covered in a
patent application by Bayer Healthcare AG.189 The prototype
N-(2-thienylmethyl) derivative (AMTB, 40, IC50 = 8 nM,
Figure 12)189 in this series was used as a pharmacological tool
to show that, in rats, this TRPM8 blocker attenuated bladder
micturition reﬂex without aﬀecting the contraction amplitude
and reduced nociceptive reﬂex responses to noxious bladder
distension.190
More recently, Pﬁzer and collaborators described new salicyl
amide derivatives with improved properties.191 Thus, following
a lead-hopping strategy from the closely related 40 (AMTB)
analogue 41, they prepared three libraries with decreasing
degree of similarity. Compound 42 from one of these libraries
displays improved potency (IC50 = 21 nM) and better lipophilic
eﬃciency compared to 41.
The HTS screening of the Pﬁzer in-house collection allowed
the identiﬁcation of another tertiary amide derivative with weak
inhibitory properties of TRPM8 receptors, which upon
optimization resulted in the quinolin-3-carboxamide derivative
PF-05105679 (43).192 Modiﬁcations at the acidic group
resulted in reduced potency, while at the other benzylic residue
only the incorporation of a m-chlorine atom is well tolerated.
Its potency against TRPM8 was conﬁrmed by patch-clamp
electrophysiology studies, and selectivity was assessed through
evaluation in a set of diﬀerent receptors, enzymes, and ion
channels, including related thermoreceptors (TRPV1 and
TRPA1) and hERG. In preclinical studies, compound 43
exhibited good oral absorption, moderate blood clearance, and
low toxicity. In humans, a single 900 mg dose was eﬀective in a
cold pressor test (phase I, NCT01393652) without signiﬁcant
changes in core body temperature, but intolerable hot sensation
side eﬀects precluded further progression into the clinic.
6.6. Other Recent TRPM8 Antagonists with Variable
Central Scaﬀolds. 6.6.1. Cyclohexane-hydantoin Spirocyclic
Derivatives. Patent WO2015136947 from Raqualia Pharma
Inc. communicates the preparation of a large collection of 1,3-
diazaspiro[4.5]decane-2,4-dione derivatives and their 1-oxa-3-
azaspiro analogues (∼600 examples), among which an array of
42 compounds potently inhibited the Ca2+ inﬂux through
HEK293 cell expressing hTRPM8 (IC50 < 10 nM, i.e., 44,
Figure 13).193 Although a central phenyl ring seems to be
preferred, some heterocyclic moieties, like pyridine, imidazole,
and pyrrole, are allowed at this position. The phenyl ring could
bear a diverse set of nitrogen heterocycles, including indole, 1-
benzimidazole, isoquinoline, and diﬀerent aza analogues, with
the 7-aza-1-benzimidazole as the most repetitive motif in highly
active compounds. Although without displaying speciﬁc data,
the inventors claimed in vitro inhibition of the Ca2+ inﬂux
through a melanoma cell line (G-31) and potent in vivo
activities in diﬀerent neuropathic pain models and on
micturition frequency.
6.6.2. Thiazole Derivatives. A patent application from
Dompe ́ Farmaceutici SpA revealed a series of compounds
with a thiazole or isoxazole central scaﬀold with interesting
activities as TRPM8 antagonists in vitro and in vivo.194 The
phenyl thiazole derivative (DFL23448, 45) was then fully
characterized in collaboration with diﬀerent academic
groups.195 It shows an IC50 value of 10 nM in cold-activated
hTRPM8 HEK-293 cells, being selective against other TRP
channels (TRPV1, TRPA1, TRPV4) and diﬀerent G-protein-
coupled receptors. In in vivo experiments in rats, 45 is able to
reduce icilin-induced wet dog shakes (10 mg/kg, iv), prolongs
the storage phase of micturition, and inhibits bladder
overactivity.
6.6.3. Menthol Derivatives. A series of menthylamine
derivatives, embodied by compound 46, elicited potent
TRPM8 antagonist properties, being between 4- and 150-fold
selective against TRPV1 and TRPA1 channels.196 When tested
on a human androgen-responsive prostate carcinoma cell line,
which overexpresses TRPM8, compound 46 induces apoptosis,
measured by the release of caspase 3/7. However, in the
androgen-unresponsive DU-145 tumor cell line, this compound
is inactive, indicating a TRPM8-dependent antitumor activity.
This compound was also progressed to Ph I clinical trials.
6.6.4. Chroman Derivatives. A large series of azachroman
derivatives was protected under patent application WO
2014025651 by Amgen Inc.197 Exempliﬁed here by compound
47, a number of these derivatives displayed nanomolar activity
in the luminescence assay of intracellular calcium (CHO
expressing hTRPM8). The most potent antagonists were able
to inhibit >90% the wet dog shakes in rats at 1 mg/kg dose.
These compounds combine in the molecule key structural
elements of other families of TRPM8 antagonists, akin to the
chroman heterocyclic ring present in 34 (Figure 9) and a
heterocyclic moiety, like the benzimidazole profusely used
within the sulfonamide derivatives.
Clinical trials (phase I, NCT01953341, NCT02132429) have
been started with AMG333 (structure not disclosed) to deﬁne
safety and tolerability and to characterize the pharmacokinetic
(PK) proﬁle as well as its eﬀect on the cold pressor test (CPT)-
induced increase in blood pressure after single oral doses in
healthy individuals and subjects with migraine.197
6.6.5. β,γ-Diaminoesters. Selective antagonists for TRPV1,
TRPM8 (48), and TRPA1 channels, as well as dual TRPV1/
TRPM8 and TRPM8/TRPA1 ligands, were obtained after
modiﬁcation of a linear β,γ-diaminoester scaﬀold.198 In this
family, no signiﬁcant diﬀerences in activity were found among
diastereoisomers of the same compound, suggesting that they
could accommodate within a big pocket within these TRP
channels. Lessons extracted from the preferred substituents for
the selective blockade of these three TRP channels could serve
to design new potent and selective TRP blockers.
6.6.6. Cinnamamide Derivatives. Some open-chain cinna-
mamide derivatives, as 49, primarily prepared as intermediates
in the synthesis of icilin derivatives, displayed pronounced
TRPM8 antagonist activity and acceptable selectivity over
TRPV1.146 Halogens or aliphatic groups at meta-position of the
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aniline-derived ring provide the most potent antagonists, with
the m-iodo derivative 49 showing a 73 nM IC50 value.
6.6.7. 3-Ylidenephthalides. A new template that resulted in
novel TRP channel modulators was the 3-ylidenephthalides.
Thus, Ortar and co-workers described that these compounds
act as TRPM8 antagonists (50, Figure 13) but also as strong
modulators of TRPA1 (activators and desensitizers).199
6.6.8. Others. Some approved antifungal drugs as
clotrimazole and econazole are also good blockers of TRPM8
channels.200,201 The phenylethyl imidazole (SKF-96365, 51),202
an inhibitor of receptor-mediated Ca2+ entry with blocking
actions on several TRPC channels, also targets and blocks
TRPM8 receptors (IC50 = 0.8 μM).
51
6.7. Natural Products and Derivatives as TRPM8
Antagonists. The well-known TRPV1 activators capsaicin
and resiniferatoxin inhibit the eﬀect on Ca2+ induced by icilin,
but not by menthol, on TRPM8-HEK-293 cells (micromolar
and submicromolar potencies, respectively).203 Anandamide
and N-arachidonoyl-dopamine (NADA, Figure 14),204 endog-
enous ligands of TRPV1 and CB1 receptors, behaved as
TRPM8 antagonists by inhibiting the Ca2+ entry stimulated
both by icilin and menthol.203 Similarly, other cannabinoid
structures of natural origin, like THC, THCA, cannabigerol,
and cannabidiol, are able to block the TRPM8 channel
activation but in general are nonselective against other TRP
channels.205 Cannabigerol, a known nonpsychotropic cannabi-
noid, is able to reduce cell viability in the colorectal cancer cell
line CACO-2 by promoting apoptosis, which was conﬁrmed by
the increased activity of caspase 3/7.206 This eﬀect on cell
viability was mimicked by two other phytocannabinoids, which
also block TRPM8, and what is more important, TRPM8
silencing resulted in a lower cytotoxic eﬀect. In vivo
experiments performed both in xenograft and AOM (azoxy-
methane) models of colon cancer showed that cannabigerol
reduces and even prevents the tumor growth. The antitumor
activity of cannabidiol on prostate cancer cell lines has also
been reported.207 These results suggest cannabigerol, cannabi-
diol, and related nonhabit analogues could be promising agents
in cancer treatment.
Figure 14. Structure of phytochemicals and derivatives acting as TRPM8 antagonists.
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Sphingoid-like compounds, like leucettamols A and B
obtained from a marine sponge, inhibit icilin-induced activation
of TRPM8 channels.208 These compounds also target the cold-
sensitive TRPA1 receptors but are inactive on TRPV1 and the
cannabinoid receptors.
Some geraniol, nerol, and citronellol derivatives behave as
TRPM8 antagonists on TRPM8-HEK293 cells, the nerol chain
being particularly eﬀective in this respect. Compound 52, with
an IC50 value of 0.29 μM in the TRPM8 assay, was selective
against TRPV1 but acts as a strong modulator of TRPA1
channels (EC50 and/or IC50 values <1 μM).
209 Similarly,
thymol derivatives, here exempliﬁed by compound 53, are true
TRPM8 antagonists, but as for most phytochemicals with
TRPM8 activity, also display strong TRPA1 modulation.210
7. INSIGHTS INTO THE TRPM8 STRUCTURE
Due to the lack of a crystal structure, little is known about the
structure−function of TRPM8, and the scarce structural
information available comes from mutagenesis experiments
and molecular modeling studies.
Similarly to voltage-gated potassium channels (Kv) and like
other TRPs, TRPM8 channels have six α-helices forming the
transmembrane architecture (S1−S6). Among them, S1−S4
segments constitute the sensing domain (SD) and S5 and S6
constitute the pore (PD). The intracellular N-domain, with an
important role in targeting TRPM8 to the plasma membrane
and also the inner C-terminal domain, containing the TRP and
coiled-coil subdomains required for gating and channel
assembly, complete the protein.211,212 The S4 transmembrane
and the S4−S5 linker are responsible for voltage sensing, S6 is
involved in the selectivity for cations and the S2−S3 linker
seems to be implicated in the interaction with icilin, the same
region that has been recognized in the activation of other TRPs
by chemical agonists.213 It has been demonstrated that the
initial N-terminal region of TRPM8 is important for correct
biogenesis and function, because truncation of the 1−40
segment augment TRPM8 responses to menthol and cold and
elimination of the 40−60 region aﬀorded nonfunctional
channels that are retained in the ER.214 The group of
Edwardson, by means of atomic force microscopy (AFM)
imaging, has showed that the TRPM8 channel assembles as a
tetramer, with a centrally located pore.215 These authors
suggest that this assembly pattern is common to other TRP
members, as they had previously shown for TRPC1,216 and
recently has been elegantly conﬁrmed by the group of Julius,
which has solved the structure of TRPV1 through cryoelectron
microscopy.217
High-throughput random mutagenesis studies on the
TRPM8 thermosensor proved that residues in S2 and S4
transmembrane segments are important for menthol-induced
channel opening and voltage and temperature activation.218
Namely, Y745 in S2 and R842 in S4 were designated as chief
residues for channel opening and menthol dependent currents
through TRPM8. Y745 is also critical for the inhibition of cold-
and voltage-activated TRPM8 currents mediated by 51 but not
by other antagonists like 30, clotrimazole, and econazole,
suggesting multiple binding sites on these channels.201 Very
recent NMR experiments on the interaction between menthol
and the hTRPM8-SD corroborate that R842 and Y745 are
essential residues for the interaction and indicated that more
likely ligand binding produces a conformational change in the
sensor domain that results in channel gating.219
Chimeric TRPM8 channels containing segments of the S6-
TRP box linker of TRPV1 permitted the identiﬁcation of
residue Tyr981 as a key molecular determinant of channel
function, while mutations in the 986−990 region inﬂuenced
channel gating by voltage and menthol. On the basis of these
results and on the cryoelectron microscopy model of TRPV1,
the group of Ferrer−Montiel generated a molecular model of
TRPM8 and hypothesized that residue Tyr981 and region
986−990 may be involved in intersubunit interactions between
the TRP domain and the S4−S5 linker (Figure 15). If the TRP
domain participates in channel opening, the modulation of
protein−protein interactions within this domain may constitute
a new strategy for channel modulation and/or drug
intervention.220
On the basis of the above model, Bertamino et al. proposed
two pharmacophore prototypes for their series of tryptamine-
based TRPM8 modulators, identifying a unique binding site for
both agonist and antagonist derivatives (15 and 38, Figures 5
and 11, respectively) but diﬀering in the interaction network.157
TRPM8 complexes with these compounds are stabilized by
similar hydrophobic interactions with Leu843, Ile701, Leu697,
a π−π stacking with Tyr754, and electrostatic pairs with the
Glu1004 side chain. The indole NH proton of agonist 23
makes hydrogen bonds with Tyr754 phenoxy group and with
Figure 15. Homology model of the tetrameric assembly of TRPM8 channel viewed from the lateral (left) and the intracellular (right) side. Each
monomer is diﬀerently colored.
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the backbone of Arg1008, increasing the Arg1008−Glu1004
distance when compared to that measured for the TRPM8−38
complex and promoting an evident shift of the TRP domain
helix. Further mutagenesis studies are needed to corroborate
the structural hypothesis depicted from these pharmacophore
models.
Pedretti and co-workers generated a full-length computer
model for the hTRPM8 channel, following a fragmental
strategy, exploiting the homology with other channel to
construct the monomer, namely the voltage-dependent Shaker
family of K+ channel for the transmembrane region and the
structure of HCN2 channel for the C-terminal domain.221
Protein−protein docking was then used to assemble monomers
into the corresponding homotetramer. Docking with menthol,
icilin, and other ligands resulted in good agreement with
mutagenesis studies, conﬁrming that S4 and S4−S5 loop are
crucial for channel activation.
The TRPM8 transmembrane and pore helix region has been
studied by Bidaux et al. using a combination of molecular
modeling and experimental techniques.222 As for other
members of the TRP family, they identiﬁed that the DDDD
ring was essential for the pore of TRPM8, with the length of
side chains and the negative charges of these residues being
crucial in TRPM8. However, unlike for other TRP channels,
the negative charge of TRPM8 D920 residue is not enough to
select divalent cations but participates in the facilitation of
cation conductance. This study also demonstrated that residue
Y908 in the P-helix is implicated in menthol and cold-mediated
TRPM8 activity but not in icilin recognition. Whether menthol
binds directly to the P-helix or to the binding site on the S2
pocket, inducing a conformational change on the pore domain
remains to be elucidated.
8. ENDOGENOUS REGULATION OF TRPM8
Traditionally, a large eﬀort has been devoted to modulating ion
channels, including TRPM8, considering that they are isolated
proteins inserted in a cell membrane. However, it is becoming
evident that ion channels are members of protein networks that
notably inﬂuence their activity. Furthermore, channel activity is
highly regulated in a context-dependent manner, with the
interplay of diverse cellular components, including lipids,
proteins, and metabolites. In this regard, the activity of
TRPM8 is prone to endogenous regulation for ﬁne-tuning its
activity to a proper cellular response. Accordingly, TRPM8
dysfunction appears also aﬀected by regulatory pathways, as
their malfunction may impact TRPM8 function.223 Undoubt-
edly, the most studied endogenous TRPM8 regulatory
mechanism is its dependence on PI(4,5)P2.
31 It is well
documented that PI(4,5)P2 modulates both activation and
desensitization of the channel.31 Hydrolysis of PI(4,5)P2 by
phospholipases type C (PLCγ, PLCβ, and PLCδ) abrogates
channel function, while resynthesis of the original PIP2 restores
its channel activation.223 Regulation of TRPM8 by phosphoi-
nositides can also be mediated by the phosphoinositide
interacting regulator of TRP (Pirt), a protein that increases
the sensitivity of TRPM8 to menthol and cool temperatures.224
This protein acts synergistically with PI(4,5)P2 to augment
TRPM8 channel activity.225
PI(4,5)P2 levels are largely modulated by the activation of
PLC through G-protein coupled receptors (GPCR) and
receptor tyrosine kinases (RTK). Activated PLC enzymes
hydrolyze PI(4,5)P2 to phosphoinositol trisphospate (PIP3)
and diacylglycerol (DAG). These two components act
synergistically to activate PKC, which in turn may phosphor-
ylate TRPM8. Furthermore, PIP3-induced release of Ca2+ from
the endoplasmic reticulum activates calmodulin kinase that can
also phosphorylate TRPM8.226 A consequence of TRPM8
phosphorylation appears to be reduction of channel activity
that further augments the inhibition produced by the hydrolysis
of PI(4,5)P2. Complementarily, an increase in PKA activity also
appears to inhibit TRPM8 channel activity. Recently, a novel
mechanism of TRPM8 inhibition by GPCRs that implies the
direct inhibition of the channel by Gαq has been described.
227 It
is notable that most RTK and GPCRs sensitize TRPV1
channels, and concomitantly desensitize TRPM8 channels,
which may underlie the heat hyperalgesia and abnormal cold
sensations caused by inﬂammation.227
The activity of TRPM8 is additionally modulated through
two additional membrane-related mechanisms. First, its
regulation by phospholipase A2 (PLA2) has been documented,
an enzyme that generates lysophospholipids and arachidonic
acid.223 Intriguingly, these lipids modulate TRPM8 activity in
some cellular systems but not in planar lipid bilayers. A
plausible explanation is that PLA2 generates two antagonistic
compounds, as lysophospholipids tend to enhance TRPM8
activity and arachidonic acid inhibits the channel function.228
Because PLA2 normally enhances menthol activity, the result is
a prevalence of the lysophospholipid stimulating eﬀect over the
polyunsaturated fatty acids inhibitory action. Second, TRPM8
activity is also modulated by its location in membrane
microdomains. For instance, it was reported that TRPM8
activity is downregulated by its partition in lipid rafts.229
However, a recent study reported just an opposite result as
TRPM8 activity was reduced after disrupting the lipid rafts in
trigeminal neurons.230 These results indicate a role of
membrane microdomains modulating channel function
although further studies are needed to clarify whether the
discrepancies reported are due to diﬀerent experimental
conditions or determined by the cellular context. Finally, the
oxidative metabolite of linoleic acid 9(S)-HODE acts a
nonselective TRPM8 antagonist, which also modulates
TRPV1 and TRPA1 channels.231
Apart from the lipid-mediated endogenous regulation, there
is evidence that TRPM8 function can be additionally
modulated by short isoforms that emerge from post-transcrip-
tional regulation of the main protein transcript.232 These
shorter channel isoforms inhibit TRPM8 activity by mimicking
an increase in temperature as compared with the inhibitory
activity exerted by chemical antagonists.232 Interestingly, a
novel TRPM8 isoform has been identiﬁed in keratinocytes that
is expressed in the endoplasmic reticulum of these cells and
endogenously contributes to the cold sensitivity of epidermal
homeostasis by controlling the balance between keratinocyte
proliferation and diﬀerentiation in a cold-dependent manner.233
Recently, it has been reported that the vesicle-associated
membrane protein 7 (VAMP7) is implicated in the functional
plasma membrane incorporation of TRPM8 and therefore in
regulating thermosensitivity.234
Another important endogenous regulatory mechanism of
TRPM8 arises from its sensitivity to sex hormones. As already
mentioned, this channel was ﬁrst identiﬁed as a biomarker of
hormone-dependent prostate cancer cells, as its levels were high
in these tumor cells.11 Asuthkar et al. report the interesting
observation that the TRPM8 channel is a receptor for
testosterone, suggesting a direct role of the hormone regulating
the receptor activity.235,236 Related to this observation, Gkika et
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al. discovered that the prostate cancer marker, prostate-speciﬁc
antigen (PSA), is also a modulator of TRPM8 activity.237
Indeed, they reported that PSA acts as a natural agonist of
TRPM8 in the prostate and the channel activation by PSA
results in a reduction of cancer cell motility. Overall, these
ﬁndings suggest that modulation of TRPM8 may be an
important strategy for anticancer drug intervention.
In summary, endogenous regulation of TRPM8 channels
provides new opportunities to modulate the receptor activity by
acting on signaling pathways that modulate the channel.
9. SUMMARY AND FUTURE PERSPECTIVES
Over the past few years, there has been signiﬁcant development
in the ﬁeld of TRPM8 channels, regarding expression,
polymodal activation, implication in diverse pathological
conditions, and discovery of diverse modulators, both agonists
and antagonists.25,33 Cumulative evidence indicates the
essential role of TRPM8 in virtually all aspects of cold thermal
transduction, including innocuous and noxious cold, hyper-
sensitivity to cold caused by inﬂammation, nerve injury, or
chemotherapeutic neuropathy, and regulation of core body
temperature.40 Therefore, modulation of TRPM8 channel
function to tune the excitability of cold-sensing neurons
could have a broad clinical beneﬁt in the management of
chronic and/or neuropathic pain.44 Thus, the identiﬁcation of
new compounds targeting diﬀerent binding sites of its
signalplex may be anticipated as a realistic strategy for
eﬀectively and safely treating acute and chronic pain states,
which is still a major unmet challenge in biomedical research.
Regarding cancer, it is documented that in prostate tissues,
TRPM8 channels play a diﬀerent role depending of the cell
type and also on the tumor grade and progression, showing
even diﬀerent and opposite eﬀects.89 TRPM8 expression in
prostate cancer cells is androgen-regulated, but its over-
expression appears to be hormone-independent. TRPM8
expression is substantially decreased in androgen-independent
and metastatic prostate cancer. A number of other life-
threatening tumors, like melanoma, neuroblastoma, and
pancreatic adenocarcinoma, also overexpress TRPM8 channels,
although their particular role is mostly unknown.88 Therefore,
there is still further research needed to completely elucidate the
mechanisms by which TRPM8 exerts its biological activity and
to understand its implications in tumorigenesis and cancer
progression. Provided that activation or blockade of the
TRPM8 channels may have opposite eﬀects, depending on
the type and stage of the tumor, their clinical signiﬁcance
remains to be proved. The proven involvement of TRPM8
channels in pain, cancer, and cancer-induced pain and its
validation as a molecular target, open the door to new global
strategies for eﬀective management of these pathologies.
Concerning diagnosis, TRPM8 levels could be exploited as a
clinical biomarker for the diagnosis of diﬀerent cancer types. In
fact, the TRPM8 detection in patient ﬂuids samples (urine and
blood) proved to be useful to discriminate between clinically
localized prostate cancer and metastatic tumors.86,101 Fur-
thermore, molecular imaging agents based on TRPM8 selective
modulators could also have a major eﬀect on the detection of
cancer, as already proposed.126
Increasing experimental evidence has also revealed that
stimulation of TRPM8 channels is involved in a number of
pathological conditions, including thermogenesis of brown
adipose tissue,113 asthma and COPD,238 urinary tract
dysfunction,239 and eye wetness.121 Thus, TRPM8 provides
promising new approaches to treat obesity, respiratory
processes, bladder dysfunction, and certain ophthalmologic
problems.
Although a number of diverse TRPM8 modulators have been
described and resulted in an improved understanding of the
structure−activity relationships within diﬀerent families, their
selectivity over other TRP channels and in general over panels
of diverse biological targets, is mostly unknown or not yet
disclosed. Furthermore, taking into account that a unique
chemotype could result in promiscuous ligands for diﬀerent
TRP channels,198 the existing pharmacological knowledge
about TRPM8 modulators should be taken with caution.
Another factor of paramount importance for the advancement
in TRPM8 drug discovery will be to elucidate the receptor
binding sites for the diﬀerent families of modulators. At present,
this is partly precluded by the scarce structural knowledge
available, although progress in homology modeling may
contribute in the near future.157 It is expected that further
advances in structural biology could help in characterizing
accurately TRPM8 ion channel−ligand interactions, thus
increasing our understanding of ligand binding. In addition, it
will contribute to apply rational design methodologies to hit
discovery and to hit-to-lead optimization toward safer and more
selective modulators. Nonetheless, until this information
becomes available, existing screening methodologies provide a
useful approach to discover novel TRPM8 modulators and to
develop analogues with improved therapeutic properties.
As reviewed in this perspective, there are few TRPM8
modulators that have reached clinical studies and most of these
have not progressed beyond phase I trials. Although the
expectations are high, prediction of a clinical success based only
on animal data appears premature at present. We have to wait
for the results of proof-of-concept clinical studies to learn on
the relevance of therapies based on TRPM8 modulators.
Finally, the information accrued thus far also suggests that
the operational function of TRPM8 depends on the cellular
context and that diﬀerent strategies, from membrane local-
ization and dynamics to translation of short isoforms, are
involved in deﬁning the pathophysiological function of the
receptor. This information should be taken into account in the
design of the next generation of TRPM8 therapeutic drug
candidates. Structure−function studies have unveiled that the
TRP domain,31 a protein region adjacent to the channel gate,
contributes to the allosteric coupling of stimuli sensing to gate
opening, and it is the binding site of PI (4,5)P2.220,240 Notably,
peptides patterned after this domain in TRPV1 channels inhibit
receptor function,228 indicating that this domain may also be a
novel site for drug intervention in TRPM8 channels. To date,
the destabilization of protein−protein interactions (PPI) within
ion channels has barely been studied,241 but most probably the
application of strategies followed for other PPIs could also be
relevant for TRPM8 drug discovery.
Another important point to be explored in the near future
would be to analyze the clinical beneﬁt of combined therapies
or multifunctional drugs acting simultaneously on several TRPs
because sometimes more than one TRP channel is involved in
the same pathological disorder (i.e., TRPM8 and TRPA1 in
cold-induced pain and asthma).107,108,242
Although ion channels remain underexploited in drug
development, continued investigation into the discovery of
new, selective TRPM8 agonists and antagonists will undoubt-
edly contribute to future progress in the ﬁeld. The ability to
combine advances in functional screening, biophysical charac-
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terization, and structure-based design techniques, along with
the generation of new chemical space to target ion channels,
will constitute a substantial challenge for the drug discovery
community in the following decade. We should eagerly await
the clinical success of currently tested TRPM8 modulators for
the treatment of human diseases from pain to cancer.
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